In our 2020 U.S. Transparency Report, we reported a 5.7% average net price decline for our medicines, marking the fourth consecutive year of such reductions. We provided $29.4 billion in rebates, discounts and fees to various healthcare entities, including private payers, government programs and providers, while investing $9.6 billion globally in research and development to discover and develop new medicines and vaccines.
Read the executive summary below, or view the full report here.
All figures according to Johnson & Johnson internal financial accounting. Figures have been rounded.